Abstract:ID 90311 Poster Board 475 The D 2 dopamine receptor (D2R) is a G protein-coupled receptor (GPCR) and a validated drug target for the treatment of many neuropsychiatric disorders, including psychosis. All currently available antipsychotics are antagonists of the D2R; however, all of these drugs exhibit polypharmacology resulting in a plethora of off-target side effects including weight gain, dysphoria, and sedation, among others. A highly-selective D2R antagonist might overcome these pitfalls and increase patient compliance with taking antipsychotic medications. Previously, our lab conducted a high-throughput screen to identify D2R-selective antagonists with reduced activity at other GPCRs. This screen identified a promising hit compound that was chemically optimized into the lead drug candidates, NCGC1360 and NCGC1366. These drug leads have relatively high binding affinities at the D2R (~80 and ~50 nM, respectively), while displaying >100-fold selectivity over the D3R and >24-fold selectivity over the D4R. A β-arrestin recruitment assay revealed even higher D2R selectivity (>100-fold) of these compounds over the D3R and D4R. In a screen against an array of 46 GPCRs, channels, and transporters using radioligand binding assays, NCGC1360 and NCGC1366 only inhibited radioligand binding to the D2R. A functional screen of 168 GPCRs further determined that NCGC1360 and NCGC1366 were exceptionally selective with each compound completely antagonizing β-arrestin recruitment to the D2R with only minor effects at a few other receptors. Schild-type analyses using dopamine-stimulated β-arrestin recruitment revealed that both compounds are competitive antagonists. A comparative molecular docking study using the active structures of both the D2R and D3R showed that NCGC1366 occupies the orthosteric binding pocket of the D2R with extended contacts with residues in extracellular loop 2 (ECL2). The contacts in ECL2 are not conserved between the D2R and D3R, which may confer D2R selectivity. We thus swapped the ECL2 of the D2R and D3R and found that a D2R mutant with the D3R ECL2 exhibited diminished affinity for NCGC1360 and NCGC1366. Conversely, a D3R mutant with the D2R ECL2 exhibited increased affinity for NCGC1360 and NCGC1366, consistent with the molecular docking study. Pharmacokinetic studies of NCGC1360 in mice revealed a half-life of 1.8 hr in plasma and 1 hr in brain with excellent brain penetration. Finally, NCGC1360 was characterized in animal models that are predicative of antipsychotic efficacy and on-target side effects. NCGC1360 dose-dependently decreased amphetamine-induced hyperlocomotion in mice and also rescued deficits in pre-pulse inhibition induced by amphetamine. Importantly, NCGC1360 did not induce catalepsy up to the highest dose tested (10 mg/kg), suggesting that it would not induce extrapyramidal side effects in patients. Taken together, these studies provide support for continuing the development of this scaffold with preclinical and IND-enabling studies. Funded by the National Institutes of Health intramural research program.

Synthesis and cytotoxic activity of peptides containing basic amino acids residues.

Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists

Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH)

Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.

Live encapsulated Lactobacillus acidophilus cells in yogurt for therapeutic oral delivery: preparation and in vitro analysis of alginate-chitosan microcapsules.

Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core

The citizen therapist and family-centered community building: introduction to a new section of the journal.

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Early endovascular salvage of a bovine pericardial superior vena cava graft.

Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT 2 Receptor Agonist

Discovery of 3-((4-benzylpyridin-2-yl)amino)benzamide Derivatives as Potent GPR52 G Protein-Biased Agonists.

Characterization of NCGC1360 and NCGC1366 as Highly-Selective D2 Dopamine Receptor Antagonists and Lead Candidates for the Treatment of Neuropsychiatric Disorders

Discovery of Biaryl Amides As Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors.

Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors

Design, synthesis and pharmacological evaluation of tricyclic derivatives as selective RXFP4 agonists

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists

Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework